Last reviewed · How we verify
Cediranib, AZD2171, RECENTIN
At a glance
| Generic name | Cediranib, AZD2171, RECENTIN |
|---|---|
| Sponsor | National Cancer Institute (NCI) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Fatigue
- Diarrhoea
- Nausea
- Hypertension
- Neutropenia
- Vomiting
- Constipation
- Stomatitis
- Neuropathy Peripheral
- Alopecia
- Thrombocytopenia
- Cough
Key clinical trials
- Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer (PHASE2)
- Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies (PHASE1)
- Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma (PHASE1, PHASE2)
- Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... (PHASE1, PHASE2)
- Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone (PHASE2)
- Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer (PHASE2)
- Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE3)
- Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cediranib, AZD2171, RECENTIN CI brief — competitive landscape report
- Cediranib, AZD2171, RECENTIN updates RSS · CI watch RSS
- National Cancer Institute (NCI) portfolio CI